Kirchgesner J, Desai RJ, Beaugerie L, Schneeweiss S, et al. Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2020 Dec 30. pii: S1542-3565(20)31726.
PMID: 33387667